Studying pancreatic ductal adenocarcinoma tumours, researchers discovered 25 antibodies that responded to antigens.
List view / Grid view
Researchers have engineered CAAR T cells to destroy harmful antibodies, improving NMDA receptor encephalitis treatment.
4 October 2023 | By Halo Labs
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
This ebook outlines Euretos’ approach to target discovery and indication expansion.
Stability attributes of biologic candidates are evaluated during early development workflows. Learn how to measure them with biophysical techniques.
Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics
25 July 2023 | By CN Bio
The webinar will explore primary concerns in drug discovery development and why drugs fail.
Tracy Saveria, James Roberts and Brian Finrow from Lumen Bioscience discuss progress in the aspiration for global vaccine access and how Lumen Bioscience’s inhalation malaria vaccine represents a major step towards it.
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further…
Researchers at the Cima University of Navarra lay the foundations for the application of an immunotherapy combination in patients with the liver cancer: hepatocellular carcinoma.
14 June 2023 | By Sartorius
Watch our virtual panel, where you'll uncover the game-changing advantages of organoids over traditional 2D cultures. Our experts will explore the immense potential of organoids in oncology and immuno-oncology research.